US

Bo Liang

This inventor holds 0 USPTO granted patents, plus 14 CIPO patents.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bo Liang. Retrieved from https://idiyas.com/inventor/bo-liang-q93luheq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

 

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Bo Liang: A Career Spanning Innovation in Therapeutics

Introduction: Bo Liang is a notable figure in the biotherapeutics sector in the United States, recognized for his contributions within several innovative companies. While he currently holds no patents, his work showcases a commitment to advancing therapeutic solutions.

Latest Patents: At this stage in his career, Bo Liang does not have any patents to his name. However, his expertise and work continue to contribute to the fields of therapeutics and biotechnologies.

Career Highlights: Bo Liang has built a meaningful career through his involvement with companies like Iview Therapeutics, Inc. and Foresight Biotherapeutics. His roles in these organizations have enabled him to work on developing significant therapeutic solutions, driving innovation in the biopharmaceutical landscape.

Collaborations: Throughout his career, Bo Liang has worked collaboratively with various teams at Iview Therapeutics, Inc. and Foresight Biotherapeutics. His collaborative spirit is integral to fostering innovation and developing new treatment methodologies.

Conclusion: Although Bo Liang does not hold patents yet, his experiences and roles in the biopharmaceutical industry reflect a dedication to innovation and research. As he continues to grow in his field, his contributions may lead to future patentable inventions that could influence therapeutic practices.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…